<DOC>
	<DOCNO>NCT01317004</DOCNO>
	<brief_summary>The purpose study evaluate change patient-reported treatment satisfaction 6 month treatment fingolimod 0.5mg/day vs. DMT standard care , use global satisfaction subscale Treatment Satisfaction Questionnaire Medication ( TSQM-9 ) .</brief_summary>
	<brief_title>Patients With Relapse Remitting Multiple Sclerosis ( RRMS ) : Candidates MS Therapy Change</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients must diagnose relapse remit MS ( RRMS ) define 2005 revise McDonald criterion . Patients explicitly agree assigned treatment group may receive fingolimod DMT inform respective benefit possible adverse event investigator . An Expanded Disability Status Scale ( EDSS ) score 05.5 inclusive . Must receive continuous treatment single approve indicated MS DMT minimum 6 month prior screen visit . Patients must continue MS DMT randomization visit . Na√Øve treatment fingolimod . A manifestation MS define inclusion criterion . A history chronic disease immune system MS know immunodeficiency syndrome . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . Patients uncontrolled diabetes mellitus ( HbA1c &gt; 7 % ) . Diagnosis macular edema Screening Phase . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Disease Modifying Therapy</keyword>
	<keyword>TSQM-9</keyword>
</DOC>